Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
REVB Price/Volume Stats
| Current price | $2.24 | 52-week high | $39.30 |
| Prev. close | $2.15 | 52-week low | $1.78 |
| Day low | $2.13 | Volume | 93,317 |
| Day high | $2.38 | Avg. volume | 338,106 |
| 50-day MA | $2.76 | Dividend yield | N/A |
| 200-day MA | $15.02 | Market Cap | 3.66M |
REVB Stock Price Chart Interactive Chart >
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
Latest REVB News From Around the Web
Below are the latest news stories about REVELATION BIOSCIENCES INC that investors may wish to consider to help them evaluate REVB as an investment opportunity.
REVB Releases Earnings and Prepares for TrialsBy Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023SAN DIEGO, November 13, 2023--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results. |
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical StudiesSAN DIEGO, October 12, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection and acute kidney injury. Data, discussed below, highlights the significant pharmacologic activity following administration of Gemini in healthy animals. Additional nonclinical biomarker an |
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities ConferenceSAN DIEGO, October 04, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming 2023 ROTH Healthcare Opportunities Conference being held in New York, NY on October 12, 2023. Mr. Rolke will also be participating in one-on-one investor meetings at the |
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of DirectorsSAN DIEGO, October 02, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company’s Board of Directors (Board). |
REVB Price Returns
| 1-mo | -1.75% |
| 3-mo | -81.96% |
| 6-mo | -88.15% |
| 1-year | -93.09% |
| 3-year | -99.98% |
| 5-year | N/A |
| YTD | -85.09% |
| 2023 | -92.47% |
| 2022 | -98.14% |
| 2021 | 1.49% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...